Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 13/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.36 |
| ▸ | CDK2 | P24941 | 2/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL583959 | 0.90 | DGAT1 (0.42) | CHEK1DGAT1CCNA2CDK2CCNA1 | |
| SCHEMBL2680051 | 0.88 | DGAT1 (0.41) | CHEK1DGAT1KDM4EHSD17B10L3MBTL1 | |
| SCHEMBL1073117 | 0.88 | DGAT1 (0.41) | CHEK1DGAT1KDM4EHSD17B10L3MBTL1 | |
| SCHEMBL1024356 | 0.87 | DGAT1 (0.52) | DGAT1KDM4EHSD17B10L3MBTL1 | |
| SCHEMBL583829 | 0.86 | KDM4E (0.39) | DGAT1KDM4EHSD17B10 | |
| SCHEMBL595034 | 0.86 | DGAT1 (0.41) | CHEK1DGAT1KDM4EHSD17B10L3MBTL1 | |
| SCHEMBL10237694 | 0.85 | CHEK1 (0.44) | CHEK1DGAT1CCNA2CDK2CCNA1 | |
| SCHEMBL601028 | 0.84 | CHEK1 (0.39) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL584319 | 0.81 | DGAT1 (0.39) | DGAT1KDM4EHSD17B10L3MBTL1 | |
| SCHEMBL2679981 | 0.81 | GPR119 (0.41) | CHEK1CCNA2CDK2CCNA1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8591943-B2 | Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-11-26 | — | — | US | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| EP-2417138-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | Schering Corporation (US) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010118207-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | CHEK1 461/4885DGAT1 3031/4885CCNA2 2476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.